global
Variables
Utilities
CUSTOM STYLES

FDA Updates Approval for Lobrena to First Line Treatment for Advanced NSCLC Patients with Changes in ALK

March 4, 2021

On March 3rd, 2021, the Food and Drug Administration (FDA) approved Lobrena (lorlatinib) for the first line treatment of non-small cell lung cancer (NSCLC) which has spread outside of the lungs that has a change in ALK identified by an FDA approved test. The FDA based their approval on the results of a clinical trial which found that patients receiving Lobrena went longer before experiencing progression than those who received Xalkori (crizotinib).The FDA’s updated approval of Lobrena gives people with lung cancer a new choice for first-line treatment.Click here to read full press release.

This is some text inside of a div block.

Lung cancer questions? Contact our free HelpLine at support@go2.org or 1-800-298-2436.